A specific immune system kinase has been found to promote tumor inflammation and progression, according to a study published in Nature Communications.
Inhibiting the kinase, called PI3K Gamma, suppressed downstream pro-cancer proteins including MLCK210, pointing to possible therapeutic application of these findings.
“The impact of the work is the demonstration that MLCK210 is a druggable target with potential utility in tumor biology,” said Daniel Watterson, PhD, the John G. Searle Professor of Molecular Biology and Biochemistry, professor of Pharmacology and a co-author of the study.
Inflammation contributes to a wide variety of diseases, including cardiovascular conditions, neurodegenerative diseases and cancer. Vascular endothelial cells and myeloid cells — monocytes, macrophages and neutrophils — play critical roles in the inflammatory response.
Myeloid cells often migrate to inflamed tissue, but sustained recruitment of these cells can cause tissue damage induced by release of oxygen radicals, which can also contribute to development of cancer. Such inflamed tissue often occurs in cancer, so controlling myeloid cell recruitment is one possible therapeutic strategy, according to the authors.
In the study, investigators stimulated myeloid cells with a cellular medium containing factors secreted by Lewis Lung carcinoma tumor cells. This medium fools myeloid cells into thinking they are in a cancerous environment, triggering behavior that closely mimics what is seen when they are recruited to the cancer sites.
The scientists discovered that in the cancer microenvironment, the kinase PI3K Gamma activates the MLCK210 protein, which facilitates recruitment of myeloid cells to sites of inflammation. Factors downstream of MLCK210 also improve myeloid cell adhesion to the lining of blood vessels and stimulate tumor progression.
Importantly, much of MLCK210 signaling is accomplished through integrins, which are transmembrane receptors that can mediate cell adhesion from within the cell, according to Watterson.
“The broader impact of this paper is the involvement of an ‘inside out’ physiological process involving MLCK210, a druggable protein kinase target,” Watterson said.
Investigators also tested reducing expression of MLCK210 in mice, finding these MLCK210-negative mice — which were developed by Watterson — had drastically reduced inflammation and tumor growth. Inhibiting the MLCK210 pathway could reduce harmful inflammation and subsequent tumor progression in cancer. These findings are being used in current development of kinase inhibitors for potential drug development, Watterson said.
Complementing the results using the MLCK21-negative mice, treatment with a small molecule inhibitor of MLCK kinase activity developed in the Watterson laboratory also reduced tumor growth and inflammation.
“The small molecule gets inside the cell and inhibits the MLCK210 activity, not the levels of the MLCK210 protein as in the genetic knockout mouse,” Watterson said. “These independent yet complementary approaches are important to demonstrate biological rigor with this pathway.”
This work was supported by National Institutes of Health grants 5R01CA226909, 5R01CA167426, and 5R01DE027325.
